An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?

We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the follo...

Full description

Saved in:
Bibliographic Details
Published in:Neoplasma 2012, Vol.59 (6), p.650-657
Main Authors: Komatsu, T, Kunieda, E, Oizumi, Y, Tamai, Y, Akiba, T
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bone Neoplasms - mortality
Bone Neoplasms - radiotherapy
Bone Neoplasms - secondary
Female
Humans
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Survival Rate
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c329t-ee6784fdbe10158e4d4ea3fe09d2dcc7cbc4bf1d572ad22c9c7e3b37b11cbbf13
cites
container_end_page 657
container_issue 6
container_start_page 650
container_title Neoplasma
container_volume 59
creator Komatsu, T
Kunieda, E
Oizumi, Y
Tamai, Y
Akiba, T
description We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the following potential prognostic factors: treatment for primary site (surgery vs. other), treatment site (spine vs. other), number of bone metastases (solitary vs. multiple), number of metastatic organs (0 vs. 1 vs. ≥2), neurological symptoms (no symptoms vs. numbness vs. paresis), degree of pain (no pain vs. mild pain vs. severe pain), performance status [PS] (0-1 vs. ≥2), biological effective dose [BED] (≥40 Gy vs.
doi_str_mv 10.4149/neo_2012_082
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1038612061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1038612061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-ee6784fdbe10158e4d4ea3fe09d2dcc7cbc4bf1d572ad22c9c7e3b37b11cbbf13</originalsourceid><addsrcrecordid>eNo1kE1LAzEQhnNQbKnePMscvawm2W8vIsUvELzoecnHbBvZJmuSrfRP-RtNtQ4DM_DOPC8zhJwzelWwor226DpOGe9ow4_InFLeZLxqyhk5C-GDpqhKyjk7ITPOm4qzsp2T7zsLwophF0wA10NcI4TJb81WDOBFRBB9RJ9abVwSvRh3YCwMk12BElYlbRTRoI0Bvkxcg3QWYYNRhJQm3EAC7xcTyYIbo9kkcpjkyrtphOhAIkSPyUr_AdZmtc60C_hrmtjOwsH59pQc92IIeHaoC_L-cP-2fMpeXh-fl3cvmcp5GzPEqm6KXktklJUNFrpAkfdIW821UrWSqpA902XNheZctarGXOa1ZEzJJOQLcvnHHb37nDDEbmOCwmEQ6ctT6BjNm4pxWu1HLw6jk9yg7kafLvS77v_H-Q_hEIJF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038612061</pqid></control><display><type>article</type><title>An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?</title><source>Alma/SFX Local Collection</source><creator>Komatsu, T ; Kunieda, E ; Oizumi, Y ; Tamai, Y ; Akiba, T</creator><creatorcontrib>Komatsu, T ; Kunieda, E ; Oizumi, Y ; Tamai, Y ; Akiba, T</creatorcontrib><description>We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the following potential prognostic factors: treatment for primary site (surgery vs. other), treatment site (spine vs. other), number of bone metastases (solitary vs. multiple), number of metastatic organs (0 vs. 1 vs. ≥2), neurological symptoms (no symptoms vs. numbness vs. paresis), degree of pain (no pain vs. mild pain vs. severe pain), performance status [PS] (0-1 vs. ≥2), biological effective dose [BED] (≥40 Gy vs. &lt;40Gy), time to distant metastasis (≥1 year vs. &lt;1 year), histology (adenocarcinoma vs. others), and use of epidermal growth factor receptor [EGFR]-targeted agents (Yes vs. No). The univariate analysis demonstrated that all factors except for the treatment site were significant. Surgery as treatment for primary site, solitary bone metastasis, no visceral organ metastasis, no symptoms or numbness, no pain, PS&lt;2, BED≥40 Gy, time to distant metastasis ≥ 1year, adenocarcinoma histology, and use of EGFR-targeted agents were correlated with a favorable prognosis. In a multivariate analysis, solitary bone metastasis, PS&lt;2, BED≥40 Gy, adenocarcinoma histology, and the use of EGFR-targeted agents were significantly correlated with a better survival (p = 0.038, 0.006, 0.003, 0.014, and &lt;0.001, respectively). A contingency table to assess the relationship between each variable and the median survival time of the patients according to the administered BED showed that in patients with the time to distant metastasis ≥ 1year and the use of EGFR-targeted agents, the subgroups treated with BED≥40 Gy had a favorable prognosis. Our study suggests that high-dose radiotherapy is associated with a better prognosis in combination with other favorable prognostic factors.</description><identifier>ISSN: 0028-2685</identifier><identifier>DOI: 10.4149/neo_2012_082</identifier><identifier>PMID: 22862159</identifier><language>eng</language><publisher>Slovakia</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms - mortality ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - secondary ; Female ; Humans ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Prognosis ; Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors ; Survival Rate</subject><ispartof>Neoplasma, 2012, Vol.59 (6), p.650-657</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-ee6784fdbe10158e4d4ea3fe09d2dcc7cbc4bf1d572ad22c9c7e3b37b11cbbf13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22862159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Komatsu, T</creatorcontrib><creatorcontrib>Kunieda, E</creatorcontrib><creatorcontrib>Oizumi, Y</creatorcontrib><creatorcontrib>Tamai, Y</creatorcontrib><creatorcontrib>Akiba, T</creatorcontrib><title>An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?</title><title>Neoplasma</title><addtitle>Neoplasma</addtitle><description>We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the following potential prognostic factors: treatment for primary site (surgery vs. other), treatment site (spine vs. other), number of bone metastases (solitary vs. multiple), number of metastatic organs (0 vs. 1 vs. ≥2), neurological symptoms (no symptoms vs. numbness vs. paresis), degree of pain (no pain vs. mild pain vs. severe pain), performance status [PS] (0-1 vs. ≥2), biological effective dose [BED] (≥40 Gy vs. &lt;40Gy), time to distant metastasis (≥1 year vs. &lt;1 year), histology (adenocarcinoma vs. others), and use of epidermal growth factor receptor [EGFR]-targeted agents (Yes vs. No). The univariate analysis demonstrated that all factors except for the treatment site were significant. Surgery as treatment for primary site, solitary bone metastasis, no visceral organ metastasis, no symptoms or numbness, no pain, PS&lt;2, BED≥40 Gy, time to distant metastasis ≥ 1year, adenocarcinoma histology, and use of EGFR-targeted agents were correlated with a favorable prognosis. In a multivariate analysis, solitary bone metastasis, PS&lt;2, BED≥40 Gy, adenocarcinoma histology, and the use of EGFR-targeted agents were significantly correlated with a better survival (p = 0.038, 0.006, 0.003, 0.014, and &lt;0.001, respectively). A contingency table to assess the relationship between each variable and the median survival time of the patients according to the administered BED showed that in patients with the time to distant metastasis ≥ 1year and the use of EGFR-targeted agents, the subgroups treated with BED≥40 Gy had a favorable prognosis. Our study suggests that high-dose radiotherapy is associated with a better prognosis in combination with other favorable prognostic factors.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors</subject><subject>Survival Rate</subject><issn>0028-2685</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1kE1LAzEQhnNQbKnePMscvawm2W8vIsUvELzoecnHbBvZJmuSrfRP-RtNtQ4DM_DOPC8zhJwzelWwor226DpOGe9ow4_InFLeZLxqyhk5C-GDpqhKyjk7ITPOm4qzsp2T7zsLwophF0wA10NcI4TJb81WDOBFRBB9RJ9abVwSvRh3YCwMk12BElYlbRTRoI0Bvkxcg3QWYYNRhJQm3EAC7xcTyYIbo9kkcpjkyrtphOhAIkSPyUr_AdZmtc60C_hrmtjOwsH59pQc92IIeHaoC_L-cP-2fMpeXh-fl3cvmcp5GzPEqm6KXktklJUNFrpAkfdIW821UrWSqpA902XNheZctarGXOa1ZEzJJOQLcvnHHb37nDDEbmOCwmEQ6ctT6BjNm4pxWu1HLw6jk9yg7kafLvS77v_H-Q_hEIJF</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Komatsu, T</creator><creator>Kunieda, E</creator><creator>Oizumi, Y</creator><creator>Tamai, Y</creator><creator>Akiba, T</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?</title><author>Komatsu, T ; Kunieda, E ; Oizumi, Y ; Tamai, Y ; Akiba, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-ee6784fdbe10158e4d4ea3fe09d2dcc7cbc4bf1d572ad22c9c7e3b37b11cbbf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Komatsu, T</creatorcontrib><creatorcontrib>Kunieda, E</creatorcontrib><creatorcontrib>Oizumi, Y</creatorcontrib><creatorcontrib>Tamai, Y</creatorcontrib><creatorcontrib>Akiba, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Neoplasma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komatsu, T</au><au>Kunieda, E</au><au>Oizumi, Y</au><au>Tamai, Y</au><au>Akiba, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?</atitle><jtitle>Neoplasma</jtitle><addtitle>Neoplasma</addtitle><date>2012</date><risdate>2012</risdate><volume>59</volume><issue>6</issue><spage>650</spage><epage>657</epage><pages>650-657</pages><issn>0028-2685</issn><abstract>We investigated the prognostic factors after radiotherapy for bone metastasis from lung cancer while taking the recent findings in the treatment of such cases into consideration. A total of 132 patients with bone metastases from pathologically confirmed lung cancer were evaluated regarding the following potential prognostic factors: treatment for primary site (surgery vs. other), treatment site (spine vs. other), number of bone metastases (solitary vs. multiple), number of metastatic organs (0 vs. 1 vs. ≥2), neurological symptoms (no symptoms vs. numbness vs. paresis), degree of pain (no pain vs. mild pain vs. severe pain), performance status [PS] (0-1 vs. ≥2), biological effective dose [BED] (≥40 Gy vs. &lt;40Gy), time to distant metastasis (≥1 year vs. &lt;1 year), histology (adenocarcinoma vs. others), and use of epidermal growth factor receptor [EGFR]-targeted agents (Yes vs. No). The univariate analysis demonstrated that all factors except for the treatment site were significant. Surgery as treatment for primary site, solitary bone metastasis, no visceral organ metastasis, no symptoms or numbness, no pain, PS&lt;2, BED≥40 Gy, time to distant metastasis ≥ 1year, adenocarcinoma histology, and use of EGFR-targeted agents were correlated with a favorable prognosis. In a multivariate analysis, solitary bone metastasis, PS&lt;2, BED≥40 Gy, adenocarcinoma histology, and the use of EGFR-targeted agents were significantly correlated with a better survival (p = 0.038, 0.006, 0.003, 0.014, and &lt;0.001, respectively). A contingency table to assess the relationship between each variable and the median survival time of the patients according to the administered BED showed that in patients with the time to distant metastasis ≥ 1year and the use of EGFR-targeted agents, the subgroups treated with BED≥40 Gy had a favorable prognosis. Our study suggests that high-dose radiotherapy is associated with a better prognosis in combination with other favorable prognostic factors.</abstract><cop>Slovakia</cop><pmid>22862159</pmid><doi>10.4149/neo_2012_082</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-2685
ispartof Neoplasma, 2012, Vol.59 (6), p.650-657
issn 0028-2685
language eng
recordid cdi_proquest_miscellaneous_1038612061
source Alma/SFX Local Collection
subjects Adult
Aged
Aged, 80 and over
Bone Neoplasms - mortality
Bone Neoplasms - radiotherapy
Bone Neoplasms - secondary
Female
Humans
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Middle Aged
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Survival Rate
title An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A36%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20analysis%20of%20the%20survival%20rate%20after%20radiotherapy%20in%20lung%20cancer%20patients%20with%20bone%20metastasis:%20is%20there%20an%20optimal%20subgroup%20to%20be%20treated%20with%20high-dose%20radiation%20therapy?&rft.jtitle=Neoplasma&rft.au=Komatsu,%20T&rft.date=2012&rft.volume=59&rft.issue=6&rft.spage=650&rft.epage=657&rft.pages=650-657&rft.issn=0028-2685&rft_id=info:doi/10.4149/neo_2012_082&rft_dat=%3Cproquest_pubme%3E1038612061%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c329t-ee6784fdbe10158e4d4ea3fe09d2dcc7cbc4bf1d572ad22c9c7e3b37b11cbbf13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1038612061&rft_id=info:pmid/22862159&rfr_iscdi=true